Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies
Status:
Terminated
Trial end date:
2021-04-05
Target enrollment:
Participant gender:
Summary
This is a single center prospective imaging study investigating the utility of hyperpolarized
C-13 pyruvate as a Biomarker of PI3K/mTOR pathway inhibition in patients with advanced solid
tumor malignancies. The current protocol will serve as a companion imaging biomarker study
paired with therapeutic trials of PI3K/mTOR pathway inhibitors (e.g. CUDC-907, BYL719), as
well as a stand-alone protocol for patients treated with standard-of-care therapies
inhibiting the PI3K/mTOR signaling pathway (eg. everolimus).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Rahul Aggarwal
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)